Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Yi Zeng, Centers for Disease Control and Prevention, China
Sponsor:
Collaborators:
Beijing Ditan Hospital
National Institutes for Food and Drug Control, China
Information provided by (Responsible Party):
Yi Zeng, Centers for Disease Control and Prevention, China
ClinicalTrials.gov Identifier:
NCT02762045
First received: May 2, 2016
Last updated: NA
Last verified: May 2016
History: No changes posted
  Purpose
This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of Adenoviral vector 5 HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy(HAART) .

Condition Intervention Phase
Acquired Immunodeficiency Syndrome
Biological: Ad5-gag
Biological: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of Recombinant Adenovirus Type 5 Therapeutic AIDS Vaccine Expressing Gag

Resource links provided by NLM:


Further study details as provided by Yi Zeng, Centers for Disease Control and Prevention, China:

Primary Outcome Measures:
  • Occurrence, intensity and relationship to vaccination of local and systemic adverse events [ Time Frame: 12 months ]
    To evaluate the safety and tolerance of a replication defective adenovirus expressing HIV-1 gag in HIV-1 infected subjects on highly active antiretroviral therapy.


Secondary Outcome Measures:
  • Immunogenicity of vaccine [ Time Frame: 24 month ]
    To evaluate immune responses pre- and post-immunization and between the vaccine and placebo groups.


Estimated Enrollment: 36
Study Start Date: April 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose Ad5-gag or Placebo
1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
Biological: Ad5-gag
Ad5-gag is used as vaccine in all arms.
Biological: Placebo
Preservation Solution is used as control in all arms.
Other Name: Preservation Solution
Experimental: Medium dose Ad5-gag or Placebo
1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
Biological: Ad5-gag
Ad5-gag is used as vaccine in all arms.
Biological: Placebo
Preservation Solution is used as control in all arms.
Other Name: Preservation Solution
Experimental: High dose Ad5-gag or Placebo
1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
Biological: Ad5-gag
Ad5-gag is used as vaccine in all arms.
Biological: Placebo
Preservation Solution is used as control in all arms.
Other Name: Preservation Solution

Detailed Description:
Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (2×10^9VP, 2×10^10VP or 2×10^11VP) injections of Adenovirus vector vaccine (Ad5-gag). Two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Are willing to participate this study and available for follow-up for the duration of the study.
  • Men and women aged 18-50 years.
  • Are HIV-positive.
  • Have been taking stable anti-HIV drugs for at least 6 months.
  • CD4 count ≥ 350 cells/mm3
  • Plasma viral load < 50 copies/ml.
  • Willing to use acceptable forms of contraception at least 21 days prior to first vaccination until 56 days after the last vaccination.

Exclusion Criteria:

  • Pregnancy or breast-feeding.
  • History of previous vaccination with an HIV-1 vaccine.
  • Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral administration, injection route or inhalation route within 6 months of study entry (But corticosteroids used for allergic rhinitis and skin topical application of corticosteroids were not included); Use of immunomodulatory agents including but not limited to interleukin-2(IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) within 30 days of study entry.
  • Use of blood products within 3 months of study entry.
  • Use of other experimental drugs within 3 months of study entry.
  • Any immunization within 3 months of study entry.
  • Comply with any of the following items: Active pulmonary tuberculosis; History of serious adverse reaction to other vaccines; Serious asthma; Have untreated thyroid disease; Syphilis
  • Laboratory values(Comply with any of the following items):

Hemoglobin < 100 g/L (male subjects),<90 g/L (female subjects); Absolute neutrophil count ≤ 1000 cells/mm3; Serum creatinine ≥15 mg/L,endogenous creatinine clearance rate <50 ml/min; alanine aminotransferase(ALT), aspartate aminotransferase(AST) ≥3× upper limit of normal range; Total bilirubin ≥2× upper limit of normal range

  • Clinically significant electrocardiogram changes.
  • Hypertension ( If it is well controlled by medication and is less than 150/100mmHg , should not be excluded) and other cardiac disease;
  • Any medical, psychiatric, social condition, occupational reason judged by the investigator that would limit the evaluation of a subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02762045

Contacts
Contact: Rongmeng Jiang, M.D. 0086-13911900791 13911900791@163.com

Locations
China
Beijing Ditan Hospital of Capital Medical University Recruiting
Beijing, China
Contact: Rongmeng Jiang, M.D.    0086-13911900791    13911900791@163.com   
Principal Investigator: Rongmeng Jiang, M.D         
Principal Investigator: Xingwang Li, M.D         
Sponsors and Collaborators
Centers for Disease Control and Prevention, China
Beijing Ditan Hospital
National Institutes for Food and Drug Control, China
Investigators
Study Director: Yi Zeng, M.D. National Institute for Viral Disease Control and Prevention, China CDC
Principal Investigator: Xia Feng, M.D. Ph.D National Institute for Viral Disease Control and Prevention, China CDC
Principal Investigator: Ke Xu, Ph.D National Institute for Viral Disease Control and Prevention, China CDC
  More Information

Responsible Party: Yi Zeng, Yi Zeng, Departement Director, Centers for Disease Control and Prevention, China, Centers for Disease Control and Prevention, China
ClinicalTrials.gov Identifier: NCT02762045     History of Changes
Other Study ID Numbers: CDCPChina
Study First Received: May 2, 2016
Last Updated: May 2, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Yi Zeng, Centers for Disease Control and Prevention, China:
Therapeutic Vaccine HIV Adenovirus type 5 vector

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Adenoviridae Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
DNA Virus Infections
Vaccines
Pharmaceutical Solutions
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2017